AUCinf	Area under the plasma concentration–time curve extrapolated to infinity
AUClast	Area under the plasma concentration–time curve to the last measurable concentration
BE	Bioequivalence
BQL	Below the quantification limit
Caco-2	Human colorectal adenocarcinoma cell line (Caco-2)
C10	Sodium caprate
C max	Maximum plasma concentration
DLS	Dynamic light scattering
DW	Distilled water
D 10	Particle diameter at 10% of the cumulative distribution
D 50	Particle diameter at 50% of the cumulative distribution
D 90	Particle diameter at 90% of the cumulative distribution
EMA	European Medicines Agency
FDA	Food and Drug Administration
f 2	Similarity factor
GI	Gastrointestinal
GLP-1 RA	Glucagon-like peptide-1 receptor agonist
HCl	Hydrochloric acid
HPLC	High-performance liquid chromatography
IACUC	Institutional Animal Care and Use Committee
IR	Immediate-release
K2-EDTA	Dipotassium ethylenediaminetetraacetic acid
k el	Terminal elimination rate constant
LC–MS/MS	Liquid chromatography–tandem mass spectrometry
LDH	Lactate dehydrogenase
LLOQ	Lower limit of quantification
LSD	Least significant difference
MCC	Microcrystalline cellulose
MCFA	Medium-chain fatty acid
MFDS	Ministry of Food and Drug Safety
MRM	Multiple-reaction monitoring
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NCA	Non-compartmental analysis
OM	Optical microscopy
Papp	Apparent permeability coefficient
PDI	Polydispersity index
PK	Pharmacokinetic(s)
QbD	Quality by design
SBL-T	Semaglutide bilayer tablet
SCC-T	Semaglutide compression-coated tablet
SD	Standard deviation
SNAC	Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate
SSL-T	Semaglutide single-layer tablet
t ½	Elimination half-life
t max	Time to maximum plasma concentration
TEER	Transepithelial electrical resistance
USP	United States Pharmacopeia